The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia

Isabel Martinez-Gras; Beatriz G. Perez-Nievas; Borja García-Bueno; José L.M. Madrigal; Eva Andrés-Esteban; Roberto Rodriguez-Jimenez; Janet Hoenicka; Tomás Palomo; Gabriel Rubio; Juan C. Leza

doi:10.1016/j.schres.2011.01.018

journal article May 01, 2011

The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia

Isabel Martinez-Gras Beatriz G. Perez-Nievas Borja García-Bueno

José L.M. Madrigal Eva Andrés-Esteban Roberto Rodriguez-Jimenez Janet Hoenicka Tomás Palomo Gabriel Rubio Juan C. Leza

Schizophrenia Research Vol. 128 No. 1-3 pp. 15-22 · Elsevier BV

View at Publisher Save 10.1016/j.schres.2011.01.018

Topics

No keywords indexed for this article. Browse by subject →

References

64

[1]

Abdel-Salam "Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat" Pharmacol. Res. (2003) 10.1016/s1043-6618(03)00106-3

[2]

Ahmed "Gender and risk of autoimmune diseases: possible role of estrogenic compounds" Environ. Health Perspect. (1999) 10.1289/ehp.99107s5681

[3]

Akiyama "Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration" Schizophr. Res. (1999) 10.1016/s0920-9964(98)00140-6

[4]

Altamura "HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatment" Eur. Neuropsychopharmacol. (1999) 10.1016/s0924-977x(99)00017-6

[5]

Arolt "Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment" Mol. Psychiatry (2000) 10.1038/sj.mp.4000650

[6]

Bechter "Mild encephalitis underlying psychiatric disorders — a reconsideration and hypothesis exemplified on Borna disease" Neurol. Psychiatry Brain Res. (2001)

[7]

Bianchi "Antidepressant drugs and experimental inflammation" Pharmacol. Res. (1996) 10.1006/phrs.1996.0032

[8]

Brodbeck "Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons" Proc. Natl Acad. Sci. USA (2008) 10.1073/pnas.0709906104

[9]

Buckley "Neurotrophins and schizophrenia" Schizophr. Res. (2007) 10.1016/j.schres.2007.01.025

[10]

Carrizo "Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives" Schizophr. Res. (2008) 10.1016/j.schres.2008.03.004

[11]

From inflammation to sickness and depression: when the immune system subjugates the brain

Robert Dantzer, Jason C. O'Connor, Gregory G. Freund et al.

Nature Reviews Neuroscience 2008 10.1038/nrn2297

[12]

Das "Increased arachidonic acid induced platelet chemiluminescence indicates cyclooxygenase overactivity in schizophrenic subjects" Prostaglandins Leukot. Essent. Fatty Acids (1998) 10.1016/s0952-3278(98)90109-0

[13]

Drexhage "Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: association with the metabolic syndrome in patients?" Schizophr. Res. (2008) 10.1016/j.schres.2008.03.018

[14]

Drexhage "Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients" Int. J. Neuropsychopharmacol. (2010) 10.1017/s1461145710000799

[15]

Eller "Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder" Prog. Neuropsychopharmacol. Biol. Psychiatry (2008) 10.1016/j.pnpbp.2007.09.015

[16]

Fan "Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia" Psychiatry Res. (2007) 10.1016/j.psychres.2006.07.011

[17]

Feinstein "Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease" Diab. Technol. Ther. (2003) 10.1089/152091503763816481

[18]

First (1995)

[19]

Forman "Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta" Proc. Natl Acad. Sci. USA (1997) 10.1073/pnas.94.9.4312

[20]

Galea "Intrinsic regulation of brain inflammatory responses" Cell. Mol. Neurobiol. (2003) 10.1023/a:1025084415833

[21]

García-Bueno "Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats" Biol. Psychiatry (2005) 10.1016/j.biopsych.2005.01.007

[22]

García-Bueno "Effects of peroxisome proliferator-activated receptor gamma agonists on brain glucose and glutamate transporters after stress in rats" Neuropsychopharmacology (2007) 10.1038/sj.npp.1301252

[23]

García-Bueno "Stress as a neuroinflammatory condition in brain: damaging and protective mechanisms" Neurosci. Biobehav. Rev. (2008) 10.1016/j.neubiorev.2008.04.001

[24]

García-Bueno "Is there a role for the nuclear receptor PPARγ in neuropsychiatric diseases?" Int. J. Neuropsychopharmacol. (2010) 10.1017/s1461145710000970

[25]

González-Scarano "Microglia as mediators of inflammatory and degenerative diseases" Annu. Rev. Neurosci. (1999) 10.1146/annurev.neuro.22.1.219

[26]

Hanson "Theories of schizophrenia: a genetic-inflammatory-vascular synthesis" BMC Med. Genet. (2005) 10.1186/1471-2350-6-7

[27]

Heneka "PPARs in the brain" Biochim. Biophys. Acta (2007) 10.1016/j.bbalip.2007.04.016

[28]

Houseknecht "Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review" Domest. Anim. Endocrinol. (2002) 10.1016/s0739-7240(01)00117-5

[29]

Jou "Mitochondrial dysfunction and psychiatric disorders" Chang Gung Med. J. (2009)

[30]

Kaiya "Elevated plasma prostaglandin E2 levels in schizophrenia" J. Neural Transm. (1989) 10.1007/bf01255817

[31]

Kapadia "Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists" Front. Biosci. (2008) 10.2741/2802

[32]

The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia

S. R. Kay, A. Fiszbein, L. A. Opler

Schizophrenia Bulletin 1987 10.1093/schbul/13.2.261

[33]

Koponen "Childhood central nervous system infections and risk for schizophrenia" Eur. Arch. Psychiatry Clin. Neurosci. (2004) 10.1007/s00406-004-0485-2

[34]

Lamason "Sexual dimorphism in immune response genes as a function of puberty" BMC Immunol. (2006) 10.1186/1471-2172-7-2

[35]

Lancaster "Suppression of lung inflammation in rats by prevention of NF-kappaB activation in the liver" Inflammation (2001) 10.1023/a:1007071527408

[36]

Lehmann "An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)" J. Biol. Chem. (1995) 10.1074/jbc.270.22.12953

[37]

Lucas "The role of inflammation in CNS injury and disease" Br. J. Pharmacol. (2006) 10.1038/sj.bjp.0706400

[38]

Maes "Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers" J. Psychiatr. Res. (1995) 10.1016/0022-3956(94)00049-w

[39]

Maes "Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs" Schizophr. Res. (1996) 10.1016/0920-9964(96)00029-1

[40]

Martinowich "New insights into BDNF function in depression and anxiety" Nat. Neurosci. (2007) 10.1038/nn1971

[41]

McIntyre "Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?" Expert Opin. Pharmacother. (2007) 10.1517/14656566.8.11.1615

[42]

Müller "A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders" Eur. Arch. Psychiatry Clin. Neurosci. (2008) 10.1007/s00406-008-2012-3

[43]

Müller "COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy" Eur. Arch. Psychiatry Clin. Neurosci. (2004) 10.1007/s00406-004-0478-1

[44]

Müller "COX-2 inhibitors as adjunctive therapy in schizophrenia" Expert Opin. Investig. Drugs (2004) 10.1517/13543784.13.8.1033

[45]

Ng "Oxidative stress in psychiatric disorders: evidence base and therapeutic implications" Int. J. Neuropsychopharmacol. (2008) 10.1017/s1461145707008401

[46]

O'Brien "Antidepressant therapy and C-reactive protein levels" Br. J. Psychiatry (2006) 10.1192/bjp.bp.105.011015

[47]

Park "Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer" Cancer Res. (2004) 10.1158/0008-5472.can-03-3924

[48]

Phillis "Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders" Brain Res. Rev. (2006) 10.1016/j.brainresrev.2006.02.002

[49]

Piletz "Pro-inflammatory biomarkers in depression: treatment with venlafaxine" World J. Biol. Psychiatry (2009) 10.3109/15622970802573246

[50]

Pollmächer "Effects of antipsychotic drugs on cytokine networks" J. Psychiatr. Res. (2000) 10.1016/s0022-3956(00)00032-7

Showing 50 of 64 references

Metrics

67

Citations

64

References

Details

Published: May 01, 2011
Vol/Issue: 128(1-3)
Pages: 15-22
License: View

Authors

I

Isabel Martinez-Gras

B

Beatriz G. Perez-Nievas

Roberto Rodriguez-Jimenez

Cite This Article

Isabel Martinez-Gras, Beatriz G. Perez-Nievas, Borja García-Bueno, et al. (2011). The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia. Schizophrenia Research, 128(1-3), 15-22. https://doi.org/10.1016/j.schres.2011.01.018

The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia

You May Also Like